340 related articles for article (PubMed ID: 35955734)
1. A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.
Newman H; Teachey DT
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955734
[TBL] [Abstract][Full Text] [Related]
2. Harnessing immunotherapy for pediatric T-cell malignancies.
Diorio C; Teachey DT
Expert Rev Clin Immunol; 2020 Apr; 16(4):361-371. PubMed ID: 32103690
[TBL] [Abstract][Full Text] [Related]
3. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
Fleischer LC; Spencer HT; Raikar SS
J Hematol Oncol; 2019 Dec; 12(1):141. PubMed ID: 31884955
[TBL] [Abstract][Full Text] [Related]
4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
5. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Angelos MG; Patel RP; Ruella M; Barta SK
Transplant Cell Ther; 2024 Feb; 30(2):171-186. PubMed ID: 37866783
[TBL] [Abstract][Full Text] [Related]
6. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
[TBL] [Abstract][Full Text] [Related]
7. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
[TBL] [Abstract][Full Text] [Related]
8. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
9. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
11. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Stem Cell Res Ther; 2021 Oct; 12(1):527. PubMed ID: 34620233
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2021; 12():765097. PubMed ID: 34777381
[TBL] [Abstract][Full Text] [Related]
13. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
14. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Rogosic S; Ghorashian S
Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
16. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
Holstein SA; Lunning MA
Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
[TBL] [Abstract][Full Text] [Related]
17. Balancing the CAR T: perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies.
Buie LW
Am J Manag Care; 2021 Aug; 27(13 Suppl):S243-S252. PubMed ID: 34407360
[TBL] [Abstract][Full Text] [Related]
18. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.
Hucks G; Rheingold SR
Blood Cancer J; 2019 Jan; 9(2):10. PubMed ID: 30670684
[TBL] [Abstract][Full Text] [Related]
19. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
20. Advances in CAR T Therapy for Hematologic Malignancies.
Freyer CW; Porter DL
Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
